Tyrosine Kinase Inhibitors in Veterinary Medicine

摘要

Tyrosine kinase inhibitors (TKIs) have become an important component of the treatment and management of a wide variety of cancers in both humans and companion animals. As of 2018 there were 37 TKIs approved by the US Food and Drug Administration (FDA), with over 150 in clinical phase trials.1 In contrast one TKI, is approved by the FDA for use in veterinary patients, toceranib phosphate (Palladia). Since approval of Palladia in 2009 it has become commonly used for the treatment of a variety of tumortypes either by itself, or in combination with other treatment modalities such as chemotherapy, and radiation therapy.2 During this presentation we will review the role of receptor tyrosine kinases (RTKs) in normal cells, how they become dysregulated incancer, how TKI work, how can we use them in veterinary patients, what are the side effects associated with TKIs and how can they be managed, and finally how should patients receiving a TKI be monitored.